Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | GUSB | P08236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242598 | 0.79 | RAB9A (0.53) | CES2CES1NPC1RAB9AMAPT | |
| SCHEMBL7274242 | 0.77 | CES2 (0.45) | CES2CES1ACKR3RAB9AMAPT | |
| SCHEMBL4240902 | 0.73 | AKR1B1 (0.45) | CES2CES1ACKR3NPC1RAB9A | |
| SCHEMBL5797417 | 0.72 | PIM1 (0.46) | NPC1RAB9APOLBL3MBTL1 | |
| SCHEMBL7269432 | 0.71 | IDO1 (0.46) | CES2CES1ACKR3RAB9AMAPT | |
| SCHEMBL2597507 | 0.71 | CES2 (0.61) | CES2CES1ACKR3NPC1RAB9A | |
| SCHEMBL3107202 | 0.71 | SHBG (0.52) | CES2CES1MAPTTP53 | |
| SCHEMBL7269421 | 0.70 | CES2 (0.50) | CES2CES1ACKR3RAB9AMAPT | |
| SCHEMBL23152719 | 0.70 | CES2 (0.59) | CES2CES1ACKR3NPC1RAB9A | |
| SCHEMBL1515773 | 0.69 | CES2 (0.53) | CES2CES1ACKR3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2170337-A1 | NOVEL TRIAZOLOPYRIDAZINES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | CES2 2517/4885CES1 1409/4885ACKR3 765/4885 |
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | HRH2, OPRD1, HRH4 | CES2 4158/4885CES1 3853/4885ACKR3 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.